{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:59:26Z","timestamp":1793257166634,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3,22]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R\/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients were enrolled in China after having progressed or not responded to prior therapy. At data cutoff, 4\u00a0patients continued treatment with 37 discontinuations. The median follow-up was 6.8 months, the ORR was 29.3%, and the complete response rate was 17.1%. Median DOR, PFS, and OS were 4.5, 2.8, and 8.4 months, respectively. Adverse events (AEs) leading to treatment discontinuation were reported in 4 patients, and grade \u2265 3 AEs were reported in 48.8% of patients. Major hemorrhage, atrial fibrillation, and\/or flutter were not observed. Zanubrutinib demonstrated modest antitumor activity in non-GCB DLBCL, like other BTK inhibitors, as well as a safety profile consistent with previous studies. Through retrospective biomarker testing, potential antitumor activity was observed in patients with both CD79B and MYD88 mutations, who have inferior outcomes to immunochemotherapy. Future studies of zanubrutinib in R\/R non-GCB DLBCL will focus on developing mechanism-based treatment combinations and biomarker-driven patient selection.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003698","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:09:37Z","timestamp":1634512177000},"page":"1629-1636","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":51,"title":["Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"6","author":[{"given":"Haiyan","family":"Yang","sequence":"first","affiliation":[{"name":"The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, West China Hospital, Sichuan Hospital, Chengdu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Beijing Cancer Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"Lymphoma Diagnosis and Therapy Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fudan University Shanghai Cancer Hospital, Shanghai, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-7131","authenticated-orcid":false,"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, The First Hospital of Jilin University, Changchun, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Lymphoma, Harbin Medical University Cancer Hospital, Harbin, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Tan","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China;"},{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China;"},{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Fu","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China;"},{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Guo","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China;"},{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Novotny","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China;"},{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Huang","sequence":"additional","affiliation":[{"name":"BeiGene (Shanghai) Co., Ltd, Shanghai, China;"},{"name":"BeiGene USA, Inc., San Mateo, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Henan Cancer Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"issue":"9","key":"2022031116284327400_B1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.24086","article-title":"Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011","volume":"90","author":"Al-Hamadani","year":"2015","journal-title":"Am J Hematol."},{"issue":"6","key":"2022031116284327400_B2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"issue":"2","key":"2022031116284327400_B3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminhematol.2015.01.006","article-title":"The histological classification of diffuse large B-cell lymphomas","volume":"52","author":"Xie","year":"2015","journal-title":"Semin Hematol."},{"issue":"2","key":"2022031116284327400_B4","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Meyer","year":"2011","journal-title":"J Clin Oncol."},{"issue":"19","key":"2022031116284327400_B5","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol."},{"issue":"1","key":"2022031116284327400_B6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","article-title":"Guidelines for the management of diffuse large B-cell lymphoma","volume":"174","author":"Chaganti","year":"2016","journal-title":"Br J Haematol."},{"issue":"2","key":"2022031116284327400_B7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40265-014-0178-8","article-title":"Ibrutinib: first global approval","volume":"74","author":"Cameron","year":"2014","journal-title":"Drugs."},{"issue":"6","key":"2022031116284327400_B8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrclinonc.2016.205","article-title":"The landscape of new drugs in lymphoma","volume":"14","author":"Younes","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"key":"2022031116284327400_B9","doi-asserted-by":"crossref","first-page":"7547","DOI":"10.1200\/JCO.2018.36.15_suppl.7547","article-title":"Acalabrutinib monotherapy in patients (pts) with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)","volume":"36","author":"Dyer","year":"2018","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022031116284327400_B10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/fon-2019-0844","article-title":"ALPINE: zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"16","author":"Hillmen","year":"2020","journal-title":"Future Oncol."},{"issue":"11","key":"2022031116284327400_B11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood."},{"key":"2022031116284327400_B12","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hon.81_2629","article-title":"Zanubrutinib plus obinutuzumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) or relapsed\/refractory (R\/R) follicular lymphoma (FL)","volume":"37","year":"2019","journal-title":"Hematol Oncol."},{"issue":"17","key":"2022031116284327400_B13","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","article-title":"Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"62","author":"Guo","year":"2019","journal-title":"J Med Chem."},{"issue":"1","key":"2022031116284327400_B14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood."},{"issue":"27","key":"2022031116284327400_B15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"2022031116284327400_B16","author":"US Food and Drug Administration"},{"key":"2022031116284327400_B17","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/21559929.1000386","article-title":"Comparison of immunohistochemistry assay results with gene expression profiling methods for diffuse large B-cell lymphoma subtype identification in matched patient samples","volume":"9","author":"Schaffer","year":"2018","journal-title":"J Mol Biomark Diagn."},{"issue":"14","key":"2022031116284327400_B18","doi-asserted-by":"crossref","first-page":"18036","DOI":"10.18632\/oncotarget.7495","article-title":"Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB\/non-GCB by immunohistochemistry is still a robust and feasible marker","volume":"7","author":"Batlle-L\u00f3pez","year":"2016","journal-title":"Oncotarget."},{"issue":"22","key":"2022031116284327400_B19","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1002\/cncr.26135","article-title":"Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype","volume":"117","author":"Hernandez-Ilizaliturri","year":"2011","journal-title":"Cancer."},{"issue":"31","key":"2022031116284327400_B20","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol."},{"key":"2022031116284327400_B21","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1158\/1538-7445.AM2015-2597","article-title":"Abstract 2597: BGB-3111 is a novel and highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor","volume":"75","author":"Li","year":"2015","journal-title":"Cancer Res."},{"issue":"23","key":"2022031116284327400_B22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1182\/blood.V126.23.832.832","article-title":"The BTK inhibitor, BGB-3111, is safe, tolerable, and highly active in patients with relapsed\/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial","volume":"126","author":"Tam","year":"2015","journal-title":"Blood."},{"issue":"8","key":"2022031116284327400_B23","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med."},{"issue":"15","key":"2022031116284327400_B24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2022031116284327400_B25","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1629\/1879498\/advancesadv2020003698.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/6\/1629\/1879498\/advancesadv2020003698.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T16:04:24Z","timestamp":1673539464000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/6\/1629\/477259\/Zanubrutinib-monotherapy-for-relapsed-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,3,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003698","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,11]]}}}